BLUE vs. VYGR, ENGN, ATYR, ITOS, ARTV, CCCC, CADL, FDMT, OCGN, and OPT
Should you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Voyager Therapeutics (VYGR), enGene (ENGN), Atyr PHARMA (ATYR), iTeos Therapeutics (ITOS), Artiva Biotherapeutics (ARTV), C4 Therapeutics (CCCC), Candel Therapeutics (CADL), 4D Molecular Therapeutics (FDMT), Ocugen (OCGN), and Opthea (OPT). These companies are all part of the "biological products, except diagnostic" industry.
bluebird bio vs.
Voyager Therapeutics (NASDAQ:VYGR) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
Voyager Therapeutics has a net margin of 15.80% compared to bluebird bio's net margin of -565.74%. Voyager Therapeutics' return on equity of 8.33% beat bluebird bio's return on equity.
bluebird bio received 648 more outperform votes than Voyager Therapeutics when rated by MarketBeat users. Likewise, 70.99% of users gave bluebird bio an outperform vote while only 67.59% of users gave Voyager Therapeutics an outperform vote.
48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 4.5% of Voyager Therapeutics shares are held by insiders. Comparatively, 1.4% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Voyager Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.
Voyager Therapeutics presently has a consensus target price of $17.43, indicating a potential upside of 188.55%. bluebird bio has a consensus target price of $49.14, indicating a potential upside of 435.33%. Given bluebird bio's higher probable upside, analysts clearly believe bluebird bio is more favorable than Voyager Therapeutics.
Voyager Therapeutics has higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, bluebird bio had 9 more articles in the media than Voyager Therapeutics. MarketBeat recorded 12 mentions for bluebird bio and 3 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.54 beat bluebird bio's score of 0.93 indicating that Voyager Therapeutics is being referred to more favorably in the media.
Summary
Voyager Therapeutics beats bluebird bio on 14 of the 19 factors compared between the two stocks.
Get bluebird bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bluebird bio Competitors List
Related Companies and Tools
This page (NASDAQ:BLUE) was last updated on 1/4/2025 by MarketBeat.com Staff
